NHS England and Capita criticised over handling of PCSE contract

NHS England and Capita criticised over handling of PCSE contract

May 21 2018  NHS England and Capita’s handling of primary care support services has...

Northern Ireland sets out details of £15m additional funding for primary care

Northern Ireland sets out details of £15m additional funding for primary care

May 15 2018 Northern Ireland is committing £15 million for enhancing primary care services...

New tax year changes to pension costs and lost reliefs will affect employers and locums

New tax year changes to pension costs and lost reliefs will affect employers and locums

April 13 2018 Changes to the minimum employer contribution to pensions and a delay in National...

BMA resource advises on how to chase up 'burdensome' late practice payments from PCSE

BMA resource advises on how to chase up 'burdensome' late practice payments from PCSE

March 9 2018 The British Medical Association has issued guidance on how to write formally to...

  • NHS England and Capita criticised over handling of PCSE contract

    NHS England and Capita criticised over handling of PCSE contract

    Monday, 21 May 2018 09:27
  • Northern Ireland sets out details of £15m additional funding for primary care

    Northern Ireland sets out details of £15m additional funding for primary care

    Tuesday, 15 May 2018 12:01
  • New tax year changes to pension costs and lost reliefs will affect employers and locums

    New tax year changes to pension costs and lost reliefs will affect employers and locums

    Friday, 13 April 2018 15:02
  • BMA resource advises on how to chase up 'burdensome' late practice payments from PCSE

    BMA resource advises on how to chase up 'burdensome' late practice payments from PCSE

    Friday, 09 March 2018 16:23

a doctor in consultation imageFebruary 9 2018

Precautions around the use of dopaminergic drugs in Parkinson’s disease are included in a new NICE Quality Standard. 


One of the five quality statements in QS 164 says that patients receiving dopaminergic therapy should be given advice about the risk of developing impulse control disorders. The quality statement has been included as “dopaminergic therapy, especially with dopamine agonists, is associated with a risk of developing impulse control disorders,” says NICE.

“It is important to discuss this risk and provide information to adults with Parkinson's disease, and their family members and carers, when starting treatment and at least annually. This will help them to recognise the symptoms and know where to get help if these develop.”

NICE expects healthcare professionals to “provide oral and written information about the risk of developing impulse control disorders to adults with Parkinson's disease when starting dopaminergic therapy (not just dopamine agonists) and discuss this with them at least annually.” They should also provide information for family members and carers if appropriate.

In addition, “oral and written information should be given about:

  • the different types of impulse control disorders (for example, compulsive gambling, hypersexuality, binge eating and obsessive shopping);
  • the increased risk of impulse control disorders developing with dopamine agonists;
  • the risk that impulse control disorders may be concealed by the person affected;
  • who to contact if impulse control disorders develop;
  • the possibility that if problematic impulse control disorders develop, dopamine agonist therapy will be reviewed and may be reduced or stopped.”

A sperate quality statement says that patients should have a point of contact with specialist services. They should also be “referred to physiotherapy, occupational therapy or speech and language therapy if they have problems with balance, motor function, activities of daily living, communication, swallowing or saliva.”

This means GPs and others need to be “aware of local referral pathways to physiotherapy, occupational therapy and speech and language therapy for adults with Parkinson’s disease.” Healthcare professionals should “carry out regular assessments of balance, motor function, activities of daily living, communication, swallowing and saliva for adults with Parkinson’s disease and refer them for physiotherapy, occupational therapy or speech and language therapy specific for Parkinson’s disease if problems are identified.”

A further quality statement says patients should have access to clozapine and patient monitoring for treating hallucinations and delusions.

The Quality Standards should be used alongside NICE guideline NG71 on Parkinson’s disease in adults.

Links:
NICE QS 164 Parkinson’s Disease           
NICE Guideline on Parkinson’s disease in adults NG71   

Management News

May 22 2018 ‘Scratch Beneath the Surface’, a new UK public health initiative intended to improve people’s understanding of atopic dermatitis, has been launched online.
May 18 2018 New guidance to support the integration of community pharmacy services into primary care homes (PCHs) has been published.  The National Association of Primary Care’s report looks at ways...